Standard BioTools
Pro forma revenues, including revenues from SomaLogic, which the firm acquired last January, were also down 9 percent.
JP Morgan Healthcare Conference, Day 4: Standard BioTools, Sera Prognostics, OraSure, Geneoscopy
Highlights from the fourth day included preliminary data from Sera Prognostics for its PreTRM blood test.
Preliminary Earnings Roundup: Hologic, Exact Sciences, QuidelOrtho, Guardant Health, More
Numerous firms reported preliminary revenues along with other business updates on Sunday and Monday ahead of the annual JP Morgan Healthcare Conference.
Standard BioTools Q3 2024 Revenues Fall 5 Percent
The company posted total revenues of $45.0 million, down from pro forma revenues of $47.4 million in Q3 2023 but beating the consensus Wall Street estimate of $41.0 million.
Standard BioTools Lowers Full-Year Revenue Guidance as Q2 Revenues Fall 23 Percent
SomaScanassay services experienced service contract delays in Q2, impacting instrument sales, CEO Michael Egholm said.